Safety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial

Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles

2005 • 44,461 citations

In silico prediction of protein-protein interactions in human macrophages

2014 • 11,120 citations

Significance analysis of microarrays applied to the ionizing radiation response

2001 • 10,393 citations

Report of an International Workshop to Standardize Response Criteria for Non-Hodgkin's Lymphomas

1999 • 3,484 citations

A Clinical Evaluation of the International Lymphoma Study Group Classification of Non-Hodgkin's Lymphoma

1997 • 2,405 citations

Follicular lymphoma international prognostic index.

2004 • 1,553 citations

Lenalidomide Causes Selective Degradation of IKZF1 and IKZF3 in Multiple Myeloma Cells

2013 • 1,552 citations

The Myeloma Drug Lenalidomide Promotes the Cereblon-Dependent Destruction of Ikaros Proteins

2013 • 1,367 citations

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

2013 • 1,338 citations

Use of Positron Emission Tomography for Response Assessment of Lymphoma: Consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma

2007 • 1,329 citations

Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group

2005 • 1,310 citations

Follicular lymphoma international prognostic index

2006 • 1,262 citations

Comparison in low-tumor-burden follicular lymphomas between an initial no-treatment policy, prednimustine, or interferon alfa: a randomized study from the Groupe d'Etude des Lymphomes Folliculaires. Groupe d'Etude des Lymphomes de l'Adulte.

1997 • 584 citations

Phase III Study of R-CVP Compared With Cyclophosphamide, Vincristine, and Prednisone Alone in Patients With Previously Untreated Advanced Follicular Lymphoma

2008 • 579 citations

Immunomodulatory agents lenalidomide and pomalidomide co‐stimulate <scp>T</scp> cells by inducing degradation of <scp>T</scp> cell repressors <scp>I</scp>karos and <scp>A</scp>iolos via modulation of the <scp>E</scp>3 ubiquitin ligase complex <scp>CRL</scp>4<scp>^CRBN</scp>

2013 • 535 citations

Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: clinical and molecular evaluation

2001 • 533 citations

Exploiting Synthetic Lethality for the Therapy of ABC Diffuse Large B Cell Lymphoma

2012 • 490 citations

Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

2008 • 422 citations

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

2008 • 420 citations

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin’s lymphoma

2011 • 389 citations

Lenalidomide Monotherapy in Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma

2008 • 375 citations

Non-Hodgkin’s Lymphomas

2010 • 337 citations

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial

2012 • 286 citations

Bayesian sequential monitoring designs for single‐arm clinical trials with multiple outcomes

1995 • 277 citations

Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications

2006 • 263 citations

Immunomodulatory drugs stimulate natural killer‐cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti‐tumour activity of rituximab in vivo

2007 • 253 citations

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

2009 • 243 citations

R-CVP Versus R-CHOP Versus R-FM for the Initial Treatment of Patients With Advanced-Stage Follicular Lymphoma: Results of the FOLL05 Trial Conducted by the Fondazione Italiana Linfomi

2013 • 240 citations

Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy

2009 • 225 citations

Rituximab Therapy for Patients With Newly Diagnosed, Advanced-Stage, Follicular Grade I Non-Hodgkin's Lymphoma: A Phase II Trial in the North Central Cancer Treatment Group

2005 • 200 citations

Oral lenalidomide with rituximab in relapsed or refractory diffuse large cell, follicular and transformed lymphoma: a phase II clinical trial

2013 • 200 citations

Lenalidomide as initial therapy of elderly patients with chronic lymphocytic leukemia

2011 • 169 citations

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

2009 • 140 citations

Single-Agent Lenalidomide in the Treatment of Previously Untreated Chronic Lymphocytic Leukemia

2010 • 137 citations

New statistical strategy for monitoring safety and efficacy in single-arm clinical trials.

1996 • 127 citations

Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials

1998 • 118 citations

Single‐agent lenalidomide in relapsed/refractory mantle cell lymphoma: results from a <scp>UK</scp> phase II study suggest activity and possible gender differences

2012 • 95 citations

A phase II study of lenalidomide in patients with extranodal marginal zone B-cell lymphoma of the mucosa associated lymphoid tissue (MALT lymphoma)

2012 • 81 citations

Biological effects and clinical significance of lenalidomide‐induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response

2011 • 66 citations

Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

2012 • 59 citations

Follicular lymphoma: 2012 update on diagnosis and management

2012 • 45 citations

Thyroid abnormalities in patients treated with lenalidomide for hematological malignancies: Results of a retrospective case review

2011 • 41 citations

CALGB 50803 (Alliance): A phase II trial of lenalidomide plus rituximab in patients with previously untreated follicular lymphoma.

2014 • 39 citations